MEDVi vs Sesame Care: Which GLP-1 Provider Is Better?
Short answer: Sesame Care scores higher on our rubric, 7.9/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.
Sesame Care beats MEDVi overall, scoring 7.9/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MEDVi is $179 first month, then $299/mo; Sesame Care is published $99/mo; total not verified. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program. Choose Sesame Care for users who want cheap fda-approved brand-name glp-1 access ($149-349/mo wegovy and zepbound via success by sesame), or insured patients who just need a prescriber.
A side-by-side look at MEDVi and Sesame Care to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
MEDVi
#46 of 54MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
Visit MEDViSesame Care
#5 of 54Telehealth marketplace offering both a low-cost consultation model ($25/visit) and the new Success by Sesame membership program ($59/mo on 3/6/12-month plans), which coordinates access to FDA-approved brand-name GLP-1 medications including Foundayo (orforglipron), Wegovy pen and pill, and Zepbound. Medication is billed separately.
Visit Sesame Care| Feature | MEDVi | Sesame Care |
|---|---|---|
| Why each one | Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication. | The broadest FDA-approved brand-name GLP-1 menu among low-cost telehealth options, Wegovy pen and pill, Zepbound, Ozempic, Mounjaro, Rybelsus, and Foundayo, coordinated through the new Success by Sesame membership at $59/mo plus medication. |
| Our Score | 5.7/10 | 7.9/10 |
| Headline Price | $179 first month, then $299/mo | published $99/mo; total not verified |
| Medication Type | Both | Both |
| Insurance Accepted | No | Yes |
| Best For | Users who want both oral and injectable compounded options in one telehealth program | Users who want cheap FDA-approved brand-name GLP-1 access ($149-349/mo Wegovy and Zepbound via Success by Sesame), or insured patients who just need a prescriber |
| Watch out for | FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication | Two distinct products (pay-per-visit vs the Success membership) sit side by side, so decide which you're buying before checkout |
| Ranking | #46 | #5 |
| Get started | Visit MEDVi | Visit Sesame Care |
Pros & Cons Compared
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping
Cons
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
- −The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Sesame Care
Pros
- +Success by Sesame program launched 2026, $59/mo on a 3/6/12-month plan, includes labs, unlimited messaging, and provider choice; medication is separate
- +Brand-name cash pricing is competitive, Wegovy pen $199 intro / $349 ongoing, Zepbound vial $299, Wegovy pill $149
- +Foundayo (Lilly's FDA-approved oral GLP-1) available as of April 2026 at $149/mo
- +Original pay-per-visit model still available at $25/consultation for users who just need a prescriber
Cons
- −Two distinct products (pay-per-visit vs the Success membership) sit side by side, so decide which you're buying before checkout
- −The $59/mo Success by Sesame rate requires a 3-month minimum commitment; month-to-month is available at $99/mo if you don't want to commit
- −Compounded meds are de-emphasized in the current marketing, the platform now leads with FDA-approved brand-name paths
- −A marketplace rather than a concierge, expect less hand-holding than dedicated subscription platforms
Our Verdict
Sesame Care edges out MEDVi with a score of 7.9/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MEDVi is $179 first month, then $299/mo; Sesame Care is published $99/mo; total not verified. Sesame Care accepts insurance, which can significantly reduce your out-of-pocket costs.
Read Full Reviews
Related comparisons
More head-to-head comparisons involving MEDVi and Sesame Care.
- MEDVi vs DudeMedsfrom $149/mo
- MEDVi vs Breeze Medsfrom $199/mo
- MEDVi vs Tonik Wellnessfrom $149/mo
- Sesame Care vs HealthRXfrom $99/mo
- Sesame Care vs Novifrom $133/mo
- Sesame Care vs TrimRxpublished $179/mo; total not verified
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Our pick of these two: Sesame Care · 7.9/10